Upregulation of hsa_circ_0004812 promotes COVID-19 cytokine storm via hsa-miR-1287-5p/IL6R, RIG-I axis

Elham Mohammadisoleimani1 | Zahra Firoozi2 | Mohammad Mehdi Naghizadeh3 | Ali Ghanbari Asad1 | Babak Pezeshki3 | Yousef Gholampour4 | Ebrahim Mirzaei3 | Mohamadhosain Simin5 | Mahsa Saliani6 | Ali Moravej7 | Zolfagh Armoon4 | Yaser Mansoori2,3

1Department of Medical Biotechnology, Fasa University of Medical Sciences, Fasa, Iran
2Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran
3Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
4Department of Internal Medicine, Fasa University of Medical Sciences, Fasa, Iran
5School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
6Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
7Department of Immunology, Fasa University of Medical Sciences, Fasa, Iran

Correspondence
Yaser mansoori, Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Email: fums.mansoori@gmail.com

Funding information
Fasa University of Medical Sciences, Grant/Award Number: 99157

Abstract
Background: SARS-CoV-2 is one of the most contagious viruses in the Coronaviridae (CoV) family, which has become a pandemic. The aim of this study is to understand more about the role of hsa_circ_0004812 in the SARS-CoV-2 related cytokine storm and its associated molecular mechanisms.

Materials and Methods: cDNA synthesis was performed after total RNA was extracted from the peripheral blood mononuclear cells (PBMC) of 46 patients with symptomatic COVID-19, 46 patients with asymptomatic COVID-19, and 46 healthy controls. The expression levels of hsa_circ_0004812, hsa-miR-1287-5p, IL6R, and RIG-I were determined using qRT-PCR, and the potential interaction between these molecules was confirmed by bioinformatics tools and correlation analysis.

Results: hsa_circ_0004812, IL6R, and RIG-I are expressed higher in the severe symptom group compared with the negative control group. Also, the relative expression of these genes in the asymptomatic group is lower than in the severe symptom group. The expression level of hsa-miR-1287-5p was positively correlated with symptoms in patients. The results of the bioinformatics analysis predicted the sponging effect of hsa_circ_0004812 as a competing endogenous RNA on hsa-miR-1287-5p. Moreover, there was a significant positive correlation between hsa_circ_0004812, RIG-I, and IL-6R expressions, and also a negative expression correlation between hsa_circ_0004812 and hsa-miR-1287-5p and between hsa-miR-1287-5p, RIG-I, and IL-6R.

Conclusion: The results of this in-vitro and in silico study show that hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I can play an important role in the outcome of COVID-19.

KEYWORDS
cytokine storm, hsa_circ_0004812, hsa-miR-1287-5p, SARS-CoV-2, sponging effect
1 | BACKGROUND

The COVID-19 pandemic has become a very challenging and controversial problem. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus is a newly emerging single-stranded RNA virus that belongs to the beta-coronavirus family and causes COVID-19 (coronavirus disease 2019). COVID-19, with a dramatic fatality rate,\textsuperscript{1-3} triggers the immune system to respond and simultaneously represses the immune response to allow the virus replication. The interplay among the infected cells, viruses, and immune system induces a high level of cytokine and chemokine secretion known as the "cytokine storm."\textsuperscript{3,4}

CircRNAs are created through the back-splicing process, which results in a closed-loop structure without poly(A) tails and 5' caps.\textsuperscript{5} These RNA molecules are highly stable and resistant to exonuclease-mediated degradation. It has been found that circRNAs, as the key regulators, could modulate gene expression through various molecular mechanisms, including a sponging effect on miRNA or acting as protein scaffolds.\textsuperscript{6}

It has been reported that noncoding RNAs could have an effect on the inflammatory cytokine storm.\textsuperscript{7} CircRNAs, which are regarded as endogenous short RNAs that may be classified into coding and noncoding circRNAs,\textsuperscript{8} play a proven role in COVID-19-related pathogenesis.\textsuperscript{9} For example, Wu et al.\textsuperscript{7} found that differentially expressed circRNAs in COVID-19 patients with recurrent disease are mainly involved in the regulation of host cell immunity and inflammation, substance and energy metabolism, cell cycle, and cell apoptosis.

The most well-known function of circRNAs is their activity as competing endogenous RNAs (ceRNAs) through a circRNA/miRNA/mRNA regulatory network.\textsuperscript{10,11} Recent evidence suggested the role of circRNAs in various viral infections such as human papilloma virus infection, herpes simplex virus, Epstein-Barr virus, human immunodeficiency virus, Middle East respiratory syndrome coronavirus, and hepatitis B virus infection and confirmed it as a potential biomarker between viral and non-viral states.\textsuperscript{12}

One of the circRNAs that has been recognized for its contribution to human viral-associated infection is hsa_circ_0004812. Hsa_circ_0004812 originated from the NINL gene and is located on chromosome 20.\textsuperscript{13} In 2020, Zhang and colleagues revealed that hsa_circ_0004812 was upregulated in chronic hepatitis B (CHB) and HBV infected hepatoma cells. Additionally, this circRNA was associated with immune suppression by HBV infection through the hsa_circ_0004812/hsa-miR-1287-5p/FSTL1 pathway.\textsuperscript{14} According to some studies, CircRNAs play an important role in gene expression as microRNA sponges via their microRNA response elements (MREs).\textsuperscript{5}

MicroRNAs have also been indicated as potential biomarkers for COVID-19 diagnosis.\textsuperscript{15} High-throughput sequencing was used during the study in 2020 to evaluate the expression levels of different miRNAs. Then, they revealed that in human patients with COVID-19, 35 miRNAs were upregulated, and 38 miRNAs were downregulated.\textsuperscript{16}

MicroRNAs are small noncoding RNAs that are about 20 to 25 nucleotides in length and act as regulators of gene expression by affecting the stability and translation of their target mRNAs.\textsuperscript{17} In this study, hsa-miR-1287-5p located on chromosome 10 was selected, which was previously predicted to have a significant binding site in the SARS-CoV-2 genome.\textsuperscript{18}

JAK/STAT is one of the pathways involved in inflammatory responses of COVID-19, such as cytokine storm.\textsuperscript{14} Interleukin 6 (IL-6) and other inflammatory components such as IL-12 and TNF are important components of cytokine storm and play a role in the pathogenesis of COVID-19 associated pneumonia.\textsuperscript{19} IL-6 can activate STAT3 during inflammatory processes, and both of them play a regulatory role in the cytokine storm in COVID-19 infection.\textsuperscript{20} Some studies indicate that IL-6R antagonists can improve the hyper-inflammation state in hospitalized COVID-19 patients.\textsuperscript{21} Retinoid-inducible gene 1 (RIG-I) is one of the retinoic acid-inducible genes I (RIG-I)-like receptor (RLR) family, playing an important role in sensing viral nucleic acids and production of pro-inflammatory and antiviral proteins.\textsuperscript{22} Interestingly, we find that hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I have an impact on cytokine storm through JAK/STAT and STAT3 signaling pathways.

The aim of this study was to develop a better understanding of the molecular mechanisms involved in COVID-19 inflammatory responses. According to the primary in-silico analysis and literature studies, we had a specific focus on the hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I axis to evaluate its potential role in COVID-19 inflammatory responses. In this regard, we assessed the expression of the members of our candidate axis, and its correlation with JAK/STAT and STAT3 signaling pathways was measured.

2 | MATERIALS AND METHODS

2.1 | Patient characteristics and sample collection

To investigate the role of hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I axis in COVID-19 viral infection, patients with SARS-CoV-2 severe symptoms (n = 46), without symptoms (n = 46), and a negative control group (n = 46) were selected for the study. The first group of patients was hospitalized at Valiasr and Shariati (Fasa, Fars, Iran). All samples were confirmed by reverse transcription-polymerase chain reaction (RT-PCR). Individuals presenting as negative controls had no respiratory insufficiency or hyperinflammation, such as bacterial and fungal infections, inflammatory bowel disease, autoimmune disorders, or cancer. We work on peripheral blood mononuclear cells (PBMC) whole blood from samples after collecting 5 μl blood samples in tubes containing EDTA in the shortest possible time. All of the participants signed a consent form, and this study was approved by the ethics committee of FUMS (IR.FUMS.REC.1399.182).

2.2 | Isolation of total RNA and cDNA synthesis

After exposing the blood cells to the reagent, PBMC were isolated using the density-gradient method. Trizol isolation reagent (Invitrogen, Thermo Fisher) was used to extract total RNA. Then,
RNA was extracted from PBMC according to the manufacturer’s instructions. The RNA purity was assessed with a NanoDrop spectrophotometer (BioTek, HTX multi-mode reader) and gel electrophoresis. The first-strand cDNA was synthesized using the PrimeScript™ RT Reagent Kit (BioFact™, Cat. No: BR441-096) following the manufacturer’s recommendations.

2.3 | Real time PCR

The relative expression of genes was determined using Power SYBR® Green PCR Master Mix (ABI, USA) on the 7500 real-time PCR system (ABI, life technology). A 15 μl reaction contained 1 μl of cDNA, 7.5 μl BioFACT™ master mix including SYBR Green (Ampliqon, Cat. No: A325402-25), 0.75 μl of each primer, and 5 μl DNase-free deionized H2O. Thermal cycling was performed at 45 cycles of 95°C for 20 s and then 60°C for 30 s. We used two internal controls, including ACTB and U48. The sequences of each primer are stated in Table 1. The Livak method (ΔΔCt) was utilized to calculate the relative expression.

2.4 | Statistical analysis

Data analysis was performed in SPSS software v.26, and graphs were drawn with GraphPad Prism v.8. Comparison of expression between the three groups of samples, including symptomatic COVID-19, asymptomatic COVID-19, and negative control, was evaluated using the Kruskal–Wallis non-parametric test. The Chi-square test was applied to compare sex and blood type between groups, and the one-way ANOVA test was used to compare age. The correlation of the elements in the hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I pathway was measured by the Spearman correlation coefficient test. A p-value less than .05 was considered a significant level.

2.5 | Bioinformatics Predictions

Hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I axis was constructed based on circRNA-miRNA pair, miRNA-mRNA pairs. CircRNA-miRNA interaction was downloaded from the database Circinteractome. The MiRWalk2.0 and miRTargetLink databases were used to predict the interaction between miRNA and mRNAs. Then, the pathway enrichment analysis of mRNA and mRNAs was performed using miRPathDB 2.0 and Enrichr databases.

3 | RESULTS

3.1 | Basic and demographic information of patients

Participants in the current study included: group (1) 46 patients with symptomatic COVID-19, including 19 (41%) females and 27 (59%) males, with a mean age of 41.54 years, group (2) 46 patients with asymptomatic COVID-19, with 21 (46%) females and 25 (54%) males, with a mean age of 47.90 years, and group (3) the negative control group with 24 (52%) males and 22 (48%), females, with a mean age of 42.65. The patients and control groups were matched in terms of age, sex, and blood group (Table 2). The most common underlying diseases in the symptomatic and asymptomatic COVID-19 groups were cardiovascular disease with 10 (22%), 12 (26%) patients and immunodeficiency disease with 4 (9%), 0 (0%) patients, respectively (Table 2). Table 3 demonstrates the different symptoms of patients with symptomatic COVID-19 participating in this study.

3.2 | Evaluation of hsa_circ_0004812, hsa-miR-1287-5p, RIG-I, and IL6R expression in symptomatic COVID-19 patients compared with asymptomatic COVID-19 patients and negative controls

We used quantitative real-time PCR to evaluate the gene expression levels in two different subgroups of COVID-19 patients and negative controls, with a total of 46 samples in each group. The expression of hsa_circ_0004812 is significantly higher in symptomatic COVID-19 samples in comparison with other groups, and it was also upregulated in asymptomatic patients compared with negative controls (Table 4, Figure 1A). The hsa-miR-1287-5p expression is obviously lower in symptomatic COVID-19 patients compared with negative controls compared with asymptomatic patients and negative controls (Table 4, Figure 1B). Furthermore, the
results indicate that RIG-I and IL6R are significantly upregulated in symptomatic and asymptomatic patients compared with negative controls (Table 3, Figure 1C,D).

3.3 | The hsa_circ_0004812 as a potential regulator of RIG-I and IL6R through sponging hsa-miR-1287-5p

To confirm whether hsa_circ_0004812 may act as the molecular sponge for hsa-miR-1287-5p, the expression correlation between these ncRNAs was evaluated in the samples. There was a significant negative correlation between the expression of hsa_circ_0004812 and hsa-miR-1287-5p \( (r = -0.283, p \text{ value} = .001, \text{Figure 2B}) \). Using bioinformatics tools, we have predicted that RIG-I and IL6R are potential targets of the hsa_circ_0004812/hsa-miR-1287-5p, and correlation analysis between scale results of RT-PCR revealed a positive expression correlation between hsa_circ_0004812 and IL6R and RIG-I \( (r = 0.760, p \text{ value} = .001, r = .236, p \text{ value} = .005, \text{Figure 2C,D}) \). In addition, the negative expression correlation between hsa-miR-1287-5p and IL6R and RIG-I was studied \( (r = -0.234, p \text{ value} = .006, r = -0.514, p \text{ value} = .001, \text{Figure 2E,F}) \). According to the results from the expression pattern of the hsa_circ_0004812/hsa-miR-1287-5p/RIG-I, IL6R axis, a distinct expression profile between COVID-19 samples and negative controls is shown by the heatmap analysis (Figure 2A). The final output confirms the significance of this hsa_circ_0004812/hsa-miR-1287-5p/RIG-I, IL6R pathway in the COVID-19 cytokine storm.

3.4 | Functional enrichment analysis of hsa_circ_0004812/hsa-miR-1287-5p/ RIG-I, IL6R axis

Using the circRNA-miRNA pair and the miRNA-mRNA pair, we generated the hsa_circ_0004812/hsa-miR-1287-5p/RIG-I, IL6R triple network. We used the miRPathDB and Enrichr databases to evaluate the association between miRNA and mRNA related pathways, respectively.\textsuperscript{26,27} "Regulatory circuits of the STAT3 signaling pathway" is the significant pathway related to hsa-miR-1287-5p via WikiPathways data \( (p \text{ value} = .006) \). Additionally, the significant gene ontology (GO) associated with IL6R and RIG-I has been shown in Figure 3. GO analysis displayed that IL6R, RIG-I, and hsa-miR-1287-5p in our proposed ceRNA regulatory network were involved in the regulation of JAK–STAT and PI3K-AKT signaling pathways.

4 | DISCUSSION

Despite the quick progression in COVID-19 research, due to the manifestation of new variants in SARS-CoV-2, COVID-19 remains a global crisis. This is largely owing to our lack of understanding of the virus’s molecular processes of pathogenesis. While the characteristics of COVID-19 vastly range from symptomatic to asymptomatic,
the cytokine storm has been triggered in the respiratory system of some of the patients.1,2 Thus, it is crucial to conduct some original research on the genetic factors that cause a dysfunctional innate immune system.

Dysregulation in circRNA expression has been linked to various diseases, including cancer, heart disease, neurological problems, and some cases of viral infection, while the underlying mechanisms remain unknown. For example, Wu et al.9 found that 114 differentially

### TABLE 3 Features of symptomatic COVID-19 patients

| Underlying disease          | Count | Column N % |
|-----------------------------|-------|------------|
| None                        | 31    | 67.4%      |
| Cardiovascular disease      | 10    | 21.7%      |
| Immune deficiency           | 5     | 10.9%      |

| Fever-tremor               |       |            |
|-----------------------------|-------|------------|
| No                          | 21    | 45.7%      |
| Yes                         | 25    | 54.3%      |

| Cough                       |       |            |
|-----------------------------|-------|------------|
| No                          | 17    | 37.0%      |
| Yes                         | 29    | 63.0%      |

| Vomiting-nausea             |       |            |
|-----------------------------|-------|------------|
| No                          | 36    | 78.3%      |
| Yes                         | 10    | 21.7%      |

| Stomachache                 |       |            |
|-----------------------------|-------|------------|
| No                          | 26    | 56.5%      |
| Yes                         | 20    | 43.5%      |

| Dizziness                   |       |            |
|-----------------------------|-------|------------|
| No                          | 33    | 71.7%      |
| Yes                         | 13    | 28.3%      |

| Headache                    |       |            |
|-----------------------------|-------|------------|
| No                          | 21    | 45.7%      |
| Yes                         | 25    | 54.3%      |

| Sore throat                 |       |            |
|-----------------------------|-------|------------|
| No                          | 23    | 50.0%      |
| Yes                         | 23    | 50.0%      |

| BMI                         |       |            |
|-----------------------------|-------|------------|
| ≤25                         | 24    | 52.2%      |
| 25–29                       | 14    | 30.4%      |
| ≥30                         | 8     | 17.4%      |

| Fatigue                     |       |            |
|-----------------------------|-------|------------|
| No                          | 27    | 58.7%      |
| Yes                         | 19    | 41.3%      |

| Diarrhea                    |       |            |
|-----------------------------|-------|------------|
| No                          | 34    | 73.9%      |
| Yes                         | 12    | 26.1%      |

### TABLE 4 Expression levels of hsa_circ_0004812, hsa-miR-1287-5p, RIG-I, and IL6R in asymptomatic and symptomatic COVID-19 patients, and negative controls (p-value computed from Kruskal–Wallis Test. p-value 1: In comparison with negative control. p-value 2: In comparison to asymptomatic covid)

| Gene name       | Group               | N   | Mean     | SD      | Median  | p-value 1 | p-value 2 |
|-----------------|---------------------|-----|----------|---------|---------|-----------|-----------|
| hsa_circ_0004812| Negative control    | 46  | 3.667    | 6.892   | 1.096   | <.001     | <.001     |
|                 | Asymptomatic covid  | 46  | 21.154   | 51.223  | 2.536   | .037      | <.001     |
|                 | Symptomatic covid   | 46  | 46.431   | 62.662  | 26.719  | <.001     | <.001     |
| hsa-miR-1287-5p | Negative control    | 46  | 2.811    | 5.895   | 1.011   | <.001     | .246      |
|                 | Asymptomatic covid  | 46  | 0.221    | 0.315   | 0.115   | <.001     | <.001     |
|                 | Symptomatic covid   | 46  | 0.225    | 0.611   | 0.047   | <.001     | <.001     |
| RIG1            | Negative control    | 46  | 4.805    | 7.503   | 1.145   | .153      | <.001     |
|                 | Asymptomatic covid  | 46  | 50.362   | 68.598  | 23.595  | <.001     | <.001     |
|                 | Symptomatic covid   | 46  | 121.466  | 113.529 | 88.392  | <.001     | <.001     |
| IL6R            | Negative control    | 46  | 4.028    | 6.615   | 0.854   | .485      | <.001     |
|                 | Asymptomatic covid  | 46  | 15.514   | 19.057  | 7.105   | <.001     | <.001     |
|                 | Symptomatic covid   | 46  | 20.332   | 17.129  | 18.700  | <.001     | <.001     |
FIGURE 1  Relative expression levels of hsa_circ_0004812, hsa-miR-1287-5p, IL6R, and RIG-I were shown in a box and whisker plot (10-90 percentile). (ns: p > .05; * p ≤ .05; *** p < .001). (A) Upregulation of hsa_circ_0004812 in COVID-19 patients compared with healthy. (B) Down expression of hsa-miR-1287-5p in COVID-19 patients compared with healthy controls. (C) Upregulation of RIG-I in COVID-19 patients compared with healthy controls. (D) Upregulation of IL6R in COVID-19 patients compared with healthy controls.
FIGURE 2  (A) LogFC heatmap of gene expression. (B) The negative correlation between hsa_circ_0004812 and hsa-miR-1287-5p expression levels in COVID-19 ($r = -0.283$, $p$ value = .001). (C) The positive correlation between hsa_circ_0004812 and IL6R expression levels in COVID-19 ($r = 0.760$, $p$ value = <.001). (D) The positive correlation between hsa_circ_0004812 and RIG-I expression levels in COVID-19 ($r = 0.236$, $p$ value = .005). (E) The negative correlation between hsa-miR-1287-5p and IL6R expression levels in COVID-19 ($r = -0.234$, $p$ value = .006). (F) The negative correlation between hsa-miR-1287-5p and RIG-I expression levels in COVID-19 ($r = -0.514$, $p$ value = <.001).
expressed circRNAs were related to exosomes that were extracted from COVID-19 patients and healthy people. In this study, using qRT-PCR, we assessed the hsa_circ_0004812, hsa-miR-1287-5p, RIG-I, and IL6R expression among the three groups of participants. Further analysis was performed to discover circRNA-miRNA, mRNA-miRNAs, and circRNA-miRNAs interactions. For confirmation of the qPCR results, in silico validation was also conducted using several databases.

Circular RNAs (circRNAs) can bind to miRNAs and act as sponges or decoys, enhancing the expression of miRNA target genes. Recently, circRNAs have been proposed as biomarkers to differentiate viral from non-viral pneumonia. Circular RNAs are involved in various activities, including immune tolerance and escape, and thus could be helpful in the emerging COVID-19 infection. The cellular mechanisms underlying circRNA dysregulation are still poorly understood in SARS-CoV-2 infection. The in silico representation...
identified a ceRNA network in SARS-CoV-infected cells by Arora et al. RNA sequencing was carried out by Zhou et al. and they discovered a total number of 99 dysregulated circRNAs that were linked to chronic hepatitis B (CHB). The study of the CHB-related circRNA-miRNA-mRNA pathway suggested that TGFβ2 was controlled by hsa_circ_0000650 through miR-6873-3p sponging. We chose hsa_circ_0004812, which is generated from the nine-in-line (NINL) gene, for further investigation among the circRNAs that have been shown to play a function in infectious illnesses.

The experimental data showed that hsa_circ_0004812 is significantly overexpressed in symptomatic COVID-19 patients as compared with asymptomatic COVID-19 patients and negative controls. In line with our analysis, previous research has indicated upregulated hsa_circ_0004812 could modulate the expression of follistatin-like 1 (FSTL1) through sponging of miR-1287-5p in CHB patients and HBV-infected hepatoma cells.

In a study, N Wang et al. introduced the IncRNA LPAL2 in thyroid eye disease (TED) by sponging the hsa-miR-1287-5p. In contrast to our study, W. Hao argues that increased miR-1287-5p levels may inhibit LPS-induced human nasal epithelial cells (HNECs) from releasing pro-inflammatory cytokines. Yajie Hu et al. reported 47 novel miRNAs with differential expression in Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) infections using high-throughput sequencing. This result of qRT-PCR of hsa-miR-1287-5p was in accordance with the high-throughput dataset. In a study, Caixia Li et al. (2020) identified 70 miRNAs dysregulated in human patients with COVID-19 by high-throughput sequencing. In the same study, by next-generation sequencing and bioinformatics tools, 55 miRNAs were altered in 10 COVID-19 patients were identified. Yajie Hu et al. reported 47 novel miRNAs with differential expression in Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) infections using high-throughput sequencing. This result of qRT-PCR of hsa-miR-1287-5p was in accordance with the high-throughput dataset.

We know circRNA acts as a microRNA sponge and modulates gene expression indirectly. The present study explored the relationship between circRNA and microRNA using a bioinformatics database and then picked out hsa-miR-1287-5p. The circRNA-interactome indicates the 7mer-1a site type between hsa_circ_00004812 and hsa-miR-1287-5p. Our results demonstrate that the hsa-miR-1287-5p is downregulated in severe symptoms COVID-19 patients compared with asymptomatic COVID-19 patients and negative controls.

Two mRNAs that we propose are related to the ceRNA are IL6R and RIG-I. Potential roles of these genes have been determined in the SARS-CoV-2 infection. The innate immune system is also activated by SARS-CoV-2 and macrophage activation causes an overproduction of pro-inflammatory cytokines, such as IL-6. In previous studies, it was found that interleukin 6 (IL-6) is a pleiotropic cytokine that controls cell proliferation and differentiation along with the immune response. Many other cytokines share this receptor component with the IL6 receptor (IL6R) and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta). Innate immune responses are generated by specific families of pattern recognition receptors.

A class of cytosolic RNA helicases known as RIG-I-like receptors (RLRs) recognizes non-self RNA that enters a cell as a result of intracellular virus replication. RIG-I, MDA5, and LGP2 are RLR proteins. These are expressed in immune and non-immune cells. Retinoic acid-inducible gene I (RIG-I) can activate type I IFN in response to SARS-CoV2 in fibroblasts and dendritic cells by activating interferon regulatory factor 3 (IRF3) via kinases.

We investigated the interaction between miRNA and mRNAs using three databases. We utilized bioinformatics to predict that hsa-miR-1287-5p could interact with IL6R and RIG-I. In the present study, we observed that the expression of IL6 and RIG-I was increased in the SARS-CoV2-infected patients with severe symptoms as compared with the asymptomatic and negative control groups. The correlation between gene expression is weak, according to the study that Ratner conducted. Additional tests would need to be performed in the future to ensure and continue the work’s results.

We evaluated the correlation between the expression levels of genes in the ceRNA regulatory network. Furthermore, we performed a correlation study between the expression of hsa_circ_0004812 and hsa-miR-1287-5p and then between hsa_circ_0004812 and IL6 and RIG-I. There was a significant negative correlation between hsa_circ_0004812 expression and hsa-miR-1287-5p expression. Additionally, our findings showed a significant positive correlation between the expression of hsa_circ_0004812 and IL6 and RIG-I. Interestingly, Zhang and colleague reported the relationships between hsa_circ_0004812 and miR-1287-5p by luciferase assays in cells transfected with pHBV. Similarly, our results demonstrate that hsa-miR-1287-5p negatively regulates IL6R and RIG-I levels in SARS-CoV2-infected patients.

5 CONCLUSION

In conclusion, the interaction of hsa_circ_0004812/hsa-miR-1287-5p/IL6R, RIG-I axis has been verified by a bioinformatics study. Gene ontology analysis indicated that the ceRNA axis is involved in the regulation of JAK-STAT and PI3K-AKT signaling pathways. COVID-19 patients related circRNA-miRNA-mRNA pathway analysis hinted that hsa_circ_0004812 regulated RIG1 and IL6R by sponging hsa-miR-1287-5p. Moreover, on the basis of the correlation analysis, it was revealed that this candidate axis is more significant in the patients with higher COVID-19 symptoms and could be considered as the potential target to be used in understanding, identifying, and treating COVID-19.

ACKNOWLEDGMENT

The authors are thankful to the patients who took part in this study.

FUNDING INFORMATION

This work was supported by Fasa University of Medical Sciences under Grant number 99157.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interests regarding the publication of this paper.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

PATIENT CONSENT STATEMENT
Informed consent was obtained from all individual participants included in the study.

ORCID
Elham Mohamadisoleimani https://orcid.org/0000-0002-3950-3102
Mohammad Mehdi Naghizadeh https://orcid.org/0000-0001-5562-103X
Ali Ghanbari Asad https://orcid.org/0000-0001-6423-4680
Yaser Mansoori https://orcid.org/0000-0002-9101-5552

REFERENCES
1. Appelberg S, Gupta S, Svensson Akusjärvi S, et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microbes Infect. 2020;9(1):1748-1760.
2. Kasela S, Ortega VE, Martorell A, et al. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Med. 2021;13(1):66.
3. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.
4. Ouyang Y, Yin J, Wang W, et al. Downregulated gene expression spectrum and immune responses changed during the disease progression in patients with COVID-19. Clin Infect Dis. 2020;71(16):2052-2060.
5. Zhang Z, Yang T, Xiao J. Circular RNAs: promising biomarkers for human diseases. EBioMedicine. 2018;34:267-274.
6. Zhang Z, Li B, Xu P, Yang B. Integrated whole transcriptome profiling and bioinformatics analysis for revealing regulatory pathways associated with quercetin-induced apoptosis in HCT-116 cells. Front Pharmacol. 2019;10:798.
7. Paniri A, Akhavan-Niaki H. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation. Life Sci. 2020;257:118114.
8. Zhao W, Zhang Y, Zhu Y. Circular RNA circ-CATC1 aggravates the malignant phenotype of non-small-cell lung cancer via encoding a peptide. J Clin Lab Anal. 2021;35(9):e23900.
9. Wu Y, Zhao T, Deng R, Xia X, Li B, Wang X. A study of differential circular RNA and lncRNA expressions in COVID-19-infected peripheral blood. Sci Rep. 2021;11(1):7991.
10. Abdollahzadeh R, Daraei A, Mansoori Y, Sepahvand M, Amoli MM, Tavakkoly-Bazzaz J. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmark of breast cancer. J Cell Physiol. 2019;234(7):10080-10100.
11. Saiani M, Mirzalebadiz A, Javadmanesh A, Slavoshi A, Ahmadian MR. KRAS-related long noncoding RNAs in human cancers. Cancer Gene Ther. 2021;29:418-427.
12. Xie H, Sun H, Mu R, et al. The role of circular RNAs in viral infection and related diseases. Virus Res. 2021;291:198205.
13. Glázár P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20(11):1666-1670.
14. Zhang L, Wang Z. Circular RNA has_circ_004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B. Viral J. 2020;17(1):40.
15. Gutierrez A, de Azeredo Lima CH, Miranda RL, Gadelha MR. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infect Genet Evol. 2020;85:104417.
16. Li C, Hu X, Li L, Li JH. Differential microRNA expression in the peripheral blood from human patients with COVID-19. J Clin Lab Anal. 2020;34(10):e23590.
17. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-655.
18. Chow JT-S, Salmena L. Prediction and analysis of SARS-CoV-2-targeting MicroRNA in human lung epithelium. Gene. 2020;11(9):1002.
19. Buonaguro FM, Puzanov I, Ascierto PA. Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020;18(1):165.
20. Hojo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020:40:37.
21. Patel K, Gooley TA, Bailey N, et al. Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients. J Intern Med. 2021;289(3):430-433.
22. Maelfait J, Beyaert R. Emerging role of ubiquitination in antiviral Rig-I signaling. Microbiol Mol Biol Rev. 2012;76(1):33-45.
23. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34-42.
24. Dewep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44(5):839-847.
25. Kern F, Aparicio-Puerta E, Li Y, et al. miRTargetLink 2.0–interactive miRNA target gene and target pathway networks. Nucleic Acids Res. 2021;49(W1):W409-w16.
26. Kehl T, Kern F, Backes C, et al. miRPathDB 2.0: a novel release of the miRNA pathway dictionary database. Nucleic Acids Res. 2019;48(D1):D142-D147.
27. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.
28. Jarlstad Olesen M, Kristensen L. Circular RNAs as microRNA sponges: evidence and controversies. Essays Biochem. 2021;65:685-696.
29. Arora S, Singh P, Dohare R, Jha R, Ali SM. Unravelling host-pathogen interactions: ceRNA RNA sponges: evidence and controversies. Essays Biochem. 2021;65:685-696.
30. Liao R, Liu L, Zhou J, Wei X, Huang P. Current molecular biology and therapeutic strategy status and prospects for circular RNAs in HBV-associated hepatocellular carcinoma. Front Oncol. 2021;11(2500):697747.
31. Wang N, Hou SY, Qi X, et al. LncRNA LPAL2/miR-1287-5p/EGFR axis modulates TED-derived orbital fibroblast activation through cell adhesion factors. J Clin Endocrinol Metab. 2021;106(8):e2866-e2886.
32. Hao W, Zhu Y, Guo Y, Wang H, miR-1287-5p upregulation inhibits the EMT and pro-inflammatory cytokines in LPS-induced human nasal epithelial cells (HNECs). Transpl Immunol. 2021;68:101429.
33. Hu Y, Song J, Liu L, et al. Comparison analysis of microRNAs in response to EV71 and CA16 infection in human bronchial epithelial cells by high-throughput sequencing to reveal differential infective mechanisms. Virus Res. 2017;228:90-101.
34. Farr RJ, Rootes CL, Rowntree LC, et al. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. 2021;17(7):e1009759.
35. Qu S, Yang X, Li X, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141-148.
36. Rostamian A, Ghazanfari T, Arabkheradmand J, et al. Interleukin-6 as a potential predictor of COVID-19 disease severity in hospitalized patients and its association with clinical laboratory routine tests. Immunoregulation. 2020;3(1):29-36.
37. Yang P, Zhao Y, Li J, et al. Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients. Cell Mol Immunol. 2021;18(4):1064-1066.
38. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
39. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20(1):17-22.
40. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730-737.
41. Kato H, Takeuchi O, Akira S. Cell type specific involvement of RIG-I in antiviral responses. Nihon Rinsho. 2006;64(7):1244-1247.
42. Ratner B. The correlation coefficient: its values range between +1/-1, or do they? J Target Meas Anal Mark. 2009;17(2):139-142.

How to cite this article: Mohammadisoleimani E, Firoozi Z, Naghizadeh MM, et al. Upregulation of hsa_circ_0004812 promotes COVID-19 cytokine storm via hsa-miR-1287-5p/IL6R, RIG-I axis. J Clin Lab Anal. 2022;00:e24666. doi: 10.1002/jcla.24666